These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33580867)

  • 1. Macrovascular Risk Equations Based on the CANVAS Program.
    Willis M; Asseburg C; Slee A; Nilsson A; Neslusan C
    Pharmacoeconomics; 2021 Apr; 39(4):447-461. PubMed ID: 33580867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort.
    Laxy M; Schöning VM; Kurz C; Holle R; Peters A; Meisinger C; Rathmann W; Mühlenbruch K; Kähm K
    Pharmacoeconomics; 2019 Dec; 37(12):1485-1494. PubMed ID: 31350720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of the CHIME simulation model to assess lifetime health outcomes of prediabetes and type 2 diabetes in Chinese populations: A modeling study.
    Quan J; Ng CS; Kwok HHY; Zhang A; Yuen YH; Choi CH; Siu SC; Tang SY; Wat NM; Woo J; Eggleston K; Leung GM
    PLoS Med; 2021 Jun; 18(6):e1003692. PubMed ID: 34166382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
    Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
    BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial Cohort.
    Keng MJ; Leal J; Mafham M; Bowman L; Armitage J; Mihaylova B
    Value Health; 2022 Mar; 25(3):435-442. PubMed ID: 35227456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study.
    Davis WA; Colagiuri S; Davis TM
    Med J Aust; 2009 Feb; 190(4):180-4. PubMed ID: 19220181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82.
    Hayes AJ; Leal J; Gray AM; Holman RR; Clarke PM
    Diabetologia; 2013 Sep; 56(9):1925-33. PubMed ID: 23793713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Blais J; Li Q; Jardine MJ; Perkovic V; Wheeler DC
    Am J Kidney Dis; 2021 Jan; 77(1):23-34.e1. PubMed ID: 32971190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
    Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
    J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing 10-Year Cardiovascular Disease Risk in Malaysians With Type 2 Diabetes Mellitus: Framingham Cardiovascular Versus United Kingdom Prospective Diabetes Study Equations.
    Yew SQ; Chia YC; Theodorakis M
    Asia Pac J Public Health; 2019 Oct; 31(7):622-632. PubMed ID: 31535566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptation of risk prediction equations for cardiovascular outcomes among patients with type 2 diabetes in real-world settings: a cross-institutional study using common data model approach.
    Yang CT; Chong KS; Wang CC; Ou HT; Kuo S
    Cardiovasc Diabetol; 2024 Jul; 23(1):244. PubMed ID: 38987773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
    Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus.
    Carbone S; Dixon DL
    Cardiovasc Diabetol; 2019 May; 18(1):64. PubMed ID: 31138195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90).
    Leal J; Alva M; Gregory V; Hayes A; Mihaylova B; Gray AM; Holman RR; Clarke P
    Diabet Med; 2021 Oct; 38(10):e14656. PubMed ID: 34297424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
    Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
    Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the IHE Cohort Model of Type 2 Diabetes and the impact of choice of macrovascular risk equations.
    Lundqvist A; Steen Carlsson K; Johansen P; Andersson E; Willis M
    PLoS One; 2014; 9(10):e110235. PubMed ID: 25310196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge.
    Si L; Willis MS; Asseburg C; Nilsson A; Tew M; Clarke PM; Lamotte M; Ramos M; Shao H; Shi L; Zhang P; McEwan P; Ye W; Herman WH; Kuo S; Isaman DJ; Schramm W; Sailer F; Brennan A; Pollard D; Smolen HJ; Leal J; Gray A; Patel R; Feenstra T; Palmer AJ
    Value Health; 2020 Sep; 23(9):1163-1170. PubMed ID: 32940234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of mortality and major cardiovascular complications in type 2 diabetes: External validation of UK Prospective Diabetes Study outcomes model version 2 in two European observational cohorts.
    Pagano E; Konings SRA; Di Cuonzo D; Rosato R; Bruno G; van der Heijden AA; Beulens J; Slieker R; Leal J; Feenstra TL
    Diabetes Obes Metab; 2021 May; 23(5):1084-1091. PubMed ID: 33377255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.
    Zhou Z; Jardine M; Perkovic V; Matthews DR; Mahaffey KW; de Zeeuw D; Fulcher G; Desai M; Oh R; Simpson R; Watts NB; Neal B
    Diabetologia; 2019 Oct; 62(10):1854-1867. PubMed ID: 31399845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
    Januzzi JL; Xu J; Li J; Shaw W; Oh R; Pfeifer M; Butler J; Sattar N; Mahaffey KW; Neal B; Hansen MK
    J Am Coll Cardiol; 2020 Nov; 76(18):2076-2085. PubMed ID: 33121714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.